Authors
Latest:
Key Takeaways and Future in Advanced Gastric Cancer TreatmentPanelists discuss how future analyses in advanced gastric cancer should assess long-term survival, real-world outcomes, biomarkers for response, resistance mechanisms, and patient selection for nivolumab plus chemotherapy. Evaluating these factors will optimize treatment strategies and confirm its role across diverse populations.
Latest:
Conducting Early Phase Trials of Promising Treatments in Neuro-OncologyShwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.
Latest:
Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-upAbiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.
Latest:
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural EffusionThis case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
Latest:
Uday R. Popat, MD, on the Future of Post-Transplant Cyclophosphamide to Prevent GVHD After Transplant for AML/MDSUday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.
Latest:
Leveraging Artificial Intelligence Evolutions in Prostate Cancer CareAI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
Latest:
Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian CancerInterim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Latest:
3 Things You Should Know About Immunotherapy in DLBCLHere are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.
Latest:
Key Takeaways on the Management of Clear-Cell RCCIn closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.
Latest:
Advanced Technology Will Help Drive Reimbursement ChangeAn industry through leader recaps current challenges to traditional reimbursement models for Medical Economics®.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Medical World News® Wellbeing Checkup: CancerNetwork® and Sonia Jhas on Easy Exercises for Busy ProfessionalsCancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for staying active on a busy, demanding schedule.
Latest:
Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate CancerBrian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
Latest:
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRCThe panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Latest:
Squamous Cell Carcinoma of the Kidney: A Large Case SeriesSyed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Latest:
Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community CenterPanelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
Latest:
Reflexology Program May Have Use in Integrative Breast Cancer CareHeather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Latest:
Kidney Cancer Research Program May Play Pivotal Role in Advancing CareAn “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Latest:
Positive Brexu-Cel Findings Raise Questions of Treatment Sequencing in B-ALLGregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.
Latest:
Providing Communicative/Evidence-Based Integrative Kidney Cancer CareAccording to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.
